Axon sells Optiscan stake

By Melissa Trudinger
Monday, 16 February, 2004

Axon Instruments (ASX:AXN) has sold its majority shareholding in Optiscan Imaging (ASX:OIL) to JF Asset Management, the Hong Kong-based Jardine Fleming institutional investment group, one of the largest fund managers in the Asia Pacific region.

JF Asset Management bought 7.8 million shares, representing 9.7 per cent of the issued shares in the company, while the remainder of the 9.6 million shares held by Axon were sold to institutional investors in Australia.

Optiscan CFO Bruce Andrew said that Axon had been one of the founding shareholders of the company, and had also provided financial support prior to the company listing.

But as a listed company, Axon recently decided to divest itself of its holdings in Optiscan as the investment no longer fit with the strategic direction of the company.

"What we are pleased about is that the shares have found a home in what promises to be a long-term supporter of the company," Andrew said. "The sale of the shares represents the respect and sensitivity that Axon has for us."

In a statement, JF Asset Management said that the group's focus was on "small caps that offered significant upside through penetration of global markets".

Related News

AusBiotech partners with Tenmile

Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...

Australian CDC issues update in wake of Ebola outbreak

After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...

Australia announces $7.2m diphtheria outbreak response package

To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd